NASDAQ:ENTA

Enanta Pharmaceuticals Stock Forecast, Price & News

$48.03

+0.36 (+0.76 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$46.88

Now: $48.03▼

$48.24

50-Day Range

$41.44

MA: $44.01▼

$48.69

52-Week Range

$38.40

Now: $48.03▼

$58.59

Volume137,447 shs

Average Volume149,503 shs

Market Capitalization$964.39 million

P/E RatioN/A

Dividend YieldN/A

Beta0.54

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.44 out of 5 stars

Medical Sector

499th out of 1,922 stocks

Pharmaceutical Preparations Industry

249th out of 771 stocks

3.2 Analyst's Opinion

Consensus Rating
Enanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $64.86, Enanta Pharmaceuticals has a forecasted upside of 35.0% from its current price of $48.03.
Amount of Analyst Coverage
Enanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Enanta Pharmaceuticals has received 286 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Enanta Pharmaceuticals has received 342 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Enanta Pharmaceuticals has received 54.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Enanta Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Enanta Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $273,480.00 in company stock.
Percentage Held by Insiders
Only 10.93% of the stock of Enanta Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.78% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.25) to ($5.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enanta Pharmaceuticals is -26.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enanta Pharmaceuticals is -26.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enanta Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ENTA

Previous Symbol

CUSIPN/A

CIK1177648

Webwww.enanta.com

Phone617-607-0800

Employees141

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio18.08

Quick Ratio18.08

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$122.47 million

Price / Sales7.87

Cash FlowN/A

Price / Cash FlowN/A

Book Value$22.70 per share

Price / Book2.12

Profitability

EPS (Most Recent Fiscal Year)($0.89)

Net Income$-36,170,000.00

Net Margins-29.53%

Return on Equity-3.75%

Return on Assets-3.53%

Miscellaneous

Outstanding Shares20,079,000

Market Cap$964.39 million

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$48.03

+0.36 (+0.76 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

How has Enanta Pharmaceuticals' stock been impacted by Coronavirus?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENTA shares have decreased by 9.2% and is now trading at $48.03.
View which stocks have been most impacted by COVID-19.

Is Enanta Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Enanta Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View analyst ratings for Enanta Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Enanta Pharmaceuticals?

Wall Street analysts have given Enanta Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enanta Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings results on Sunday, November, 22nd. The biotechnology company reported ($1.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.95) by $0.51. The biotechnology company earned $23.63 million during the quarter, compared to the consensus estimate of $25.63 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 3.75% and a negative net margin of 29.53%.
View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

7 analysts have issued 12 month price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $30.00 to $107.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $64.86 in the next year. This suggests a possible upside of 35.0% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Enanta Pharmaceuticals' key competitors?

Some companies that are related to Enanta Pharmaceuticals include Legend Biotech (LEGN), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), Corcept Therapeutics (CORT), Cryoport (CYRX), Prelude Therapeutics (PRLD), I-Mab (IMAB), Rocket Pharmaceuticals (RCKT), ALX Oncology (ALXO), CytoDyn (CYDY), Nektar Therapeutics (NKTR), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO) and Pacira BioSciences (PCRX).
View all of ENTA's competitors.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:

Dr. Jay R. Luly, Pres, CEO & Director (Age 65, Pay $998.3k)
Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 66, Pay $581.29k)
Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 69, Pay $636.02k)
Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 67, Pay $588.49k)
Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 55, Pay $620.01k)
Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. Communications
Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel.

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.89%), State of Alaska Department of Revenue (0.07%), Exchange Traded Concepts LLC (0.04%), Nisa Investment Advisors LLC (0.03%) and Pacer Advisors Inc. (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner, Paul J Mellett and Yat Sun Or.
View institutional ownership trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, Exchange Traded Concepts LLC, and Pacer Advisors Inc..
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $48.03.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $964.39 million and generates $122.47 million in revenue each year. The biotechnology company earns $-36,170,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Enanta Pharmaceuticals employs 141 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here